Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome

UPDATE: Barrington Research Assumes Coverage On Haemonetics On Positive Revenue Outlook


In a report published Thursday, Barrington Research analyst Michael Petusky assumed coverage on Haemonetics Corporation (NYSE: HAE) with an Outperform rating and $46.00 price target.

In the report, Barrington Research noted, “Our price target is $46 and we arrive at our target by attaching a 11x multiple to our 2016 adjusted EBITDA estimate of $245.0 million and a 10.3x multiple to our 2017 adjusted EBITDA estimate of $262.7.0 million. We feel a 10-12x multiple range is appropriate for companies like Haemonetics whose businesses contains elements of both a devices company, as well as a healthcare services business.”

Haemonetics closed on Wednesday at $36.41.

Latest Ratings for HAE

May 2019UpgradesMarket PerformOutperform
Aug 2018MaintainsOverweightOverweight
Jun 2018MaintainsBuyBuy

View More Analyst Ratings for HAE
View the Latest Analyst Ratings

Posted-In: Barrington Research Michael PetuskyAnalyst Color Initiation Analyst Ratings


Related Articles (HAE)

View Comments and Join the Discussion!

Latest Ratings

FRPTInitiates Coverage On60.0
NOMDInitiates Coverage On26.0
SMPLInitiates Coverage On27.0
TWNKInitiates Coverage On16.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: CRT Capital Reiterates On Williams-Sonoma On Broad-Based Strength Heading Into Holiday

UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided